This is a working overview of neuropeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Infected dogs carry the highest bacterial load of B. canis after 1-6 months after infection. Infected neutered animals are not able to display reproductive symptoms, however both intact and neutered dogs are able to shed B. canis in urine. This means that both neutered and intact dogs are able to transmit the disease via urine. B. canis is found to be localized in the prostate of male dogs, thus transmitting through the urine in both intact and neutered males. It has been suggested that male dogs carry higher concentrations of the bacteria when compared to female dogs due contamination from seminal fluid. Neutered dogs are also capable of shedding the bacteria in their saliva and nasal secretions. B. canis is the least common cause of Brucellosis in humans. Transmission to humans is rarely diagnosed but is possible. It can be transmitted via bodily fluids and aborted material. Signs and symptoms are very non-specific, such as fever, joint pain, and fatigue. The disease can also be debilitating, causing conditions such as endocarditis, splenomegaly, or neurologic symptoms.
== Anti-aging protocol == In 2019, Johnson stated he had for years maintained health-compromising habits, due to the demands of entrepreneurship and as a young father. He started improving his well-being through standard health interventions before shifting toward anti-aging experimentation in 2021. In 2023, Johnson underwent a series of monthly 1-liter plasma transfusions over a six month period. One of these six transfusions was a tri-generational transfusion experiment, with Johnson's 17 year old son serving as the donor for Johnson, then Johnson was himself donor for his father. He says he will not repeat the transfusions due to lack of benefits. The FDA has stated that transfusions such as the kind Johnson had are without benefit and may be harmful. Johnson follows a strict dietary and lifestyle regimen in pursuit of life extension. Since 2023, Johnson has publicly shared his biomarker data and engaged in competitive biohacking against other people. The idea was recommended by Kate Tolo. In 2025, Johnson recorded a DunedinPACE speed of aging score at 0.503 per calendar year. DunedinPACE is a DNA methylation biomarker used to estimate the pace of biological aging. His attempts have been met with criticism from some experts in fields related to aging. Moshe Szyf, a professor of pharmacology and therapeutics at McGill University, has expressed skepticism that science is yet capable of achieving the remarkable results that Johnson claims to be reaching.
In 1912, Jardine, Matheson & Co. and the Keswicks would eventually buy out the shares of the Matheson family in the firm although the name is still retained. The company was managed by several of Jardine's family members and their descendants throughout the decades, including the Keswicks, Buchanan-Jardines, Landales, Bell-Irvings, Patersons, Newbiggings and Weatheralls. Notable Jardines managing directors, or taipans, included Sir Alexander Matheson, 1st Baronet, David Jardine, Robert Jardine, William Keswick, James Johnstone Keswick, Ben Beith, David Landale, Sir John Buchanan-Jardine, Sir William Johnstone "Tony" Keswick, Hugh Barton, Sir Michael Herries, Sir John Keswick, Sir Henry Keswick, Simon Keswick and Alasdair Morrison. There was a point in time in the early 20th century that the firm had two taipans at the same time, one in Hong Kong and one in Shanghai, to effectively manage the firm's extensive affairs in both locations. Both taipans were responsible only to the senior partner or proprietor in London who was normally a retired former taipan and an elder member of the Jardine family. Today, the Jardine Matheson Group is still very much active in Hong Kong, being one of the largest conglomerates in Hong Kong and its largest employer, second only to the government. Several landmarks in present-day Hong Kong are named after the firm and the founders Jardine and Matheson like Jardine's Bazaar, Jardine's Crescent, Jardine's Bridge, Jardine's Lookout, Yee Wo Street, Matheson Street, Jardine House and the Noon Day Gun.
Ruthenium has no radioactive isotopes with half-lives much longer than a year and the price of ruthenium is relatively high, making the destruction of 99Tc into a potentially lucrative source of producing a precious metal from an undesirable feedstock.
Sources: en.wikipedia.org
=== Political === During their campaigns against both the Saleh and Hadi governments, Houthis used civil disobedience. Following the Yemeni government's decision on 13 July 2014 to increase fuel prices, Houthi leaders succeeded in organising massive rallies in the capital, Sanaa, to protest the decision and to demand resignation of the incumbent government of Abd Rabbuh Mansur Hadi for "state-corruption". These protests developed into the 2014–2015 phase of the insurgency. Similarly, following 2015 Saudi-led airstrikes against Houthis which claimed civilians lives, Yemenis responded to Abdul-Malik al-Houthi's call and took to streets of Sanaa by the tens of thousands to voice their anger at the Saudi invasion. The movement's expressed goals include combating economic underdevelopment and political marginalization in Yemen while seeking greater autonomy for Houthi-majority regions of the country. One of its spokespeople, Mohammed al-Houthi, said in 2018 that he supports a democratic republic in Yemen. The Houthis have made fighting corruption the centerpiece of their political program.
Certain functions necessary to the trial, such as monitoring and lab work, may be managed by an outsourced partner, such as a contract research organization or a central laboratory. Only 10 percent of all drugs started in human clinical trials become approved drugs. Data collection is a key activity within clinical trials and digital data collection tools can assist greatly in this effort.
== Etymology and history == By the late 17th and early 18th centuries, the digestion of meat by stomach secretions and the conversion of starch to sugars by plant extracts and saliva were known but the mechanisms by which these occurred had not been identified. French chemist Anselme Payen was the first to discover an enzyme, diastase, in 1833. A few decades later, when studying the fermentation of sugar to alcohol by yeast, Louis Pasteur concluded that this fermentation was caused by a vital force contained within the yeast cells called "ferments", which were thought to function only within living organisms. He wrote that "alcoholic fermentation is an act correlated with the life and organization of the yeast cells, not with the death or putrefaction of the cells." In 1877, German physiologist Wilhelm Kühne (1837–1900) first used the term enzyme, which comes from Ancient Greek ἔνζυμον (énzymon) 'leavened, in yeast', to describe this process. The word enzyme was used later to refer to nonliving substances such as pepsin, and the word ferment was used to refer to chemical activity produced by living organisms.
== Research == Pentoxifylline is a synthetic methylxanthine derivative that is commonly used for peripheral vascular disease, but has also been researched as a possible treatment for Peyronie's disease. It's proposed to act through multiple mechanisms, including antioxidant, antifibrotic (including reducing TGF-β), and anti-inflammatory pathways, to interfere with the disease's pathogenesis and reduce symptoms such as penile curvature, pain, and plaque volume. While systematic reviews indicate a lack of consistent large-scale evidence for its efficacy, various clinical studies and case reports suggest that pentoxifylline, especially in combination with other therapies, may effectively reduce the progression of Peyronie's disease.
Through strengthening adhesion, α2β1 integrin facilitates aggregation of extra platelets and the development of a stable thrombus that is capable of stopping the bleeding. The engagement of collagen receptors through α2β1 integrin stimulates inside-out signaling and platelet spreading as well as remodeling of the cytoskeleton. This results in increased surface area of platelets, making their contact with surrounding platelets and coagulation factors possible. Platelet adhesion being important for physiological hemostasis, any variations in the expression of ITGA2 gene or its products may affect the rate of bleeding or development of thrombosis. There are some polymorphism of the ITGA2 gene, the presence of which results in various collagen-binding capacities in people due to different densities of the α2β1 receptor on the platelets' surface. Though the impact of these variations is still unclear, their relation to myocardial infarction and Ischemic stroke has been studied. Therefore, α2β1 receptor still remains an interesting Therapeutic target for the prevention of pathological thrombosis.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.